Prosecution Insights
Last updated: April 19, 2026

Orion Corporation

5 pending office actions

Portfolio Summary

5
Total Pending OAs
1
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18555291 TEAD INHIBITORS O DELL, DAVID K 1621 Non-Final OA Oct 13, 2023
18551059 TASIPIMIDINE FORMULATIONS AND USE THEREOF SAMSELL, RILLA MARIE 1624 Non-Final OA Sep 18, 2023
18255218 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER FETTEROLF, BRANDON J 1626 Non-Final OA May 31, 2023
17924857 CYP11A1 INHIBITORS SCHMIDT, IZABELA MARIA 1621 Non-Final OA Nov 11, 2022
17623925 METHODS FOR ADMINISTERING (R)-N-[4-(1,4,5,6-TETRAHYDRO-6-OXO-3-PYRIDAZINYL)PHENYL]ACETAMIDE DAHLIN, HEATHER RAQUEL 1629 Final Rejection Dec 30, 2021

Managing Orion Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month